research Expert consensus on systemic treatment activation and grading evaluation for alopecia areata
Experts recommend starting systemic treatment for alopecia areata when the condition is severe or causes significant distress.
Search
for
Sort by
Research
660-690 / 1000+ resultsresearch Table 1_Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study.docx
Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.
research Comparative Efficacy of Topical Calcipotriol, Intralesional Autologous Platelet-Rich Plasma Injection, and Combined Topical Calcipotriol with Intralesional Autologous Platelet-Rich Plasma Injection on Patients with Alopecia Areata
The combination of calcipotriol and PRP is the most effective treatment for alopecia areata.
research Intralesional Methotrexate versus Triamcinolone Acetonide for Localized Alopecia Areata (AA) Treatment
Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Pediatric and Adolescent Alopecia Areata Treated with JAK Inhibitors: Balancing Efficacy and Safety Across Clinical Trials
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
research Race and Ethnicity Sub-Groups of Alopecia Areata Patients have Differing Clinical Characteristics: TARGET-DERM AA
Alopecia areata severity and symptoms vary by race and ethnicity.
research Treatment of Alopecia Areata using Transdermal Delivery of 5-Fluorouracil by Fractional CO2 Laser versus Intralesional Injection of 5-Fluorouracil
Transdermal delivery using a fractional CO2 laser is more effective for treating alopecia areata than injections.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Is thyroid dysfunction a common cause of telogen effluvium?: A retrospective study
Hypothyroidism is often linked to the hair loss condition telogen effluvium.
research Growth Factors and Microneedling in Alopecia Areata: A Narrative Review
Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
research Alopesia universalis pada anak yang berespon baik dengan terapi kombinasi: sebuah laporan kasus
A young child with complete hair loss improved significantly with a combination of hair growth treatments and laser therapy.
research Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
research Retrospective Analysis of Pediatric Alopecia Areata Treated with Methotrexate
Methotrexate may effectively and safely treat hair loss in children, with notable improvement after 12-15 months.
research Successful Treatment of Alopecia Totalis with Topical Calcipotriol: Serial Case Report and Review of the Literature
Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.
research 1315 An Integrated model of alopecia areata biomarkers highlights both Th1/Th2 upregulation, with stronger correlations between Th2 activation and disease severity
Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
research Investigating the mechanisms underlying effects of testosterone on blood pressure in normotensive and hypertensive rats / Loh Su Yi
Testosterone raises blood pressure by affecting kidney function and brain gene regulation over time.
research Study of the base influence on the foaming properties gel shampoo with minoxidil
Anionic surfactants significantly improve the foaming of minoxidil gel shampoo.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research Limitations of Treatment-Induced Alopecia Grading Instruments in Evaluating Therapeutic Response
Current methods for grading hair loss from cancer treatment are not accurate enough and need improvement.
research Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study
Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
research AYURVEDIC MANAGEMENT OF ALOPECIA AREATA USING VIDDHAKARMA AS A PARA-SURGICAL PROCEDURE: A CASE STUDY
Viddhakarma may effectively regrow hair in alopecia areata without side effects.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
research Effectiveness of Abrocitinib in Adolescent Alopecia Areata: A Prospective Observational Pilot Study
Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.